Bevacizumab improves BCVA and central macular thickness in CSME patients

Article

Multiple injections of bevacizumab improve best-corrected visual acuity (BCVA) and central macular thickness in patients with persistant clinically significant macular oedema (CSME)

Recent Videos
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.